Colchicine treatment in 12,602 ACS patients did not significantly reduce the primary composite endpoint of cardiovascular death, MI, stroke, or urgent revascularization (OR 0.82, P=0.15).
Does colchicine reduce the composite of cardiovascular death, recurrent myocardial infarction, stroke or urgent/unplanned revascularization in patients with acute or recent acute coronary syndrome?
In a meta-analysis of 12,602 patients with recent ACS, colchicine did not significantly reduce the composite of cardiovascular death, recurrent MI, stroke, or urgent revascularization compared to placebo.
Absolute Event Rate: 0% vs 0%
Abstract Background Inflammation is a leading cause of ischaemic heart disease. The aim of the present study is to assess whether the treatment with colchicine, a well-known anti-inflammatory drug, in patients with ACS is associated with improved cardiovascular outcomes. Methods We conducted a systematic review and meta-analysis ofrandomized clinical trials (RCTs) of patients enrolled at the time of an acute or recent ACS and treated with colchicine versus placebo. PubMed, Scopus, and the Cochrane Central Register of Controlled Trials databases were searched. The primary endpoint was composite of cardiovascular death, recurrent myocardial infarction, stroke or urgent/unplanned revascularization. Other endpoints were individual components of the primary end point, all-cause death, non-cardiovascular death, and diarrhea. Results Three RCTs were included, involving a total of 12,602 patients. There was no significant difference in the primary composite endpoint between the colchicine and placebo groups (OR 0.82, 95% CI 0.63-1.07, P=0.15). Analysis of individual components of the primary endpoint also revealed no significant differences between the colchicine vs. placebo groups: cardiovascular deaths (P=0.89), recurrent myocardial infarctions (P=0.17), strokes (P=0.27), urgent/unplanned revascularizations (P=0.14), all-cause death (P=0.95), non-cardiovascular death (P=0.98;), and diarrhea (P=0.08). Conclusions The use of colchicine in patients with recent acute myocardial infarction was not associated with reduced cardiovascular events. No increased all-cause or non-cardiovascular mortality were observed.
Cappannoli et al. (Sat,) reported a other. Colchicine treatment in 12,602 ACS patients did not significantly reduce the primary composite endpoint of cardiovascular death, MI, stroke, or urgent revascularization (OR 0.82, P=0.15).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: